Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

Authors Zaragoza R, Pemán J, Salavert M, Viudes Á, Solé A, Jarque I, Monte E, Romá E, Cantón E

Published 5 December 2008 Volume 2008:4(6) Pages 1261—1280

DOI https://doi.org/10.2147/TCRM.S3994

Review by Single-blind

Peer reviewer comments 3

Rafael Zaragoza1, Javier Pemán2, Miguel Salavert3, Ángel Viudes2, Amparo Solé4, Isidro Jarque5, Emilio Monte6, Eva Romá6, Emilia Cantón7

1Servicio de Medicina Intensiva, Hospital Universitario Dr Peset, Valencia, Spain; 2Servicio de Microbiología; 3Unidad de Enfermedades Infecciosas; 4Unidad de Trasplante Pulmonar; 5Servicio de Hematología; 6Servicio de Farmacia; 7Unidad de Microbiología Experimental, Centro de Investigación, Hospital Universitario La Fe Valencia, Spain

Abstract: The high morbidity, mortality, and health care costs associated with invasive fungal infections, especially in the critical care setting and immunocompromised host, have made it an excellent target for prophylactic, empiric, and preemptive therapy interventions principally based on early identification of risk factors. Early diagnosis and treatment are associated with a better prognosis. In the last years there have been important developments in antifungal pharmacotherapy. An approach to the new diagnosis tools in the clinical mycology laboratory and an analysis of the use new antifungal agents and its application in different clinical situations has been made. Furthermore, an attempt of developing a state of the art in each clinical scenario (critically ill, hematological, and solid organ transplant patients) has been performed, trying to choose the best strategy for each clinical situation (prophylaxis, pre-emptive, empirical, or targeted therapy). The high mortality rates in these settings make mandatory the application of early de-escalation therapy in critically ill patients with fungal infection. In addition, the possibility of antifungal combination therapy might be considered in solid organ transplant and hematological patients.

Keywords: invasive fungal infections, prophylaxis, empirical therapy, preemptive treatment, targeted therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Cationic star-shaped polymer as an siRNA carrier for reducing MMP-9 expression in skin fibroblast cells and promoting wound healing in diabetic rats

Li N, Luo HC, Yang C, Deng JJ, Ren M, Xie XY, Lin DZ, Yan L, Zhang LM

International Journal of Nanomedicine 2014, 9:3377-3387

Published Date: 15 July 2014

Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes

Magnus Dencker, Martin Stagmo, Mozhgan Dorkhan

Vascular Health and Risk Management 2010, 6:373-382

Published Date: 18 May 2010

Bortezomib in the management of multiple myeloma

Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al

Cancer Management and Research 2009, 1:107-117

Published Date: 8 September 2009

Management of postoperative nausea and vomiting: focus on palonosetron

Neil A Muchatuta, Michael J Paech

Therapeutics and Clinical Risk Management 2009, 5:21-34

Published Date: 30 November 2008

Cerebral blood flow response to flavanol-rich cocoa in healthy elderly humans

Farzaneh A Sorond, Lewis A Lipsitz, Norman K Hollenberg, Naomi DL Fisher

Neuropsychiatric Disease and Treatment 2008, 4:433-440

Published Date: 11 April 2008

Alemtuzumab in the up-front setting

Matthew Kaufman, Kanti R Rai

Therapeutics and Clinical Risk Management 2008, 4:459-464

Published Date: 11 April 2008

Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology

Cleber A Trujillo, Arthur A Nery, Janaí­na M Alves, Antonio H Martins, Henning Ulrich

Clinical Ophthalmology 2007, 1:393-402

Published Date: 15 February 2008

A review of the use of adapalene for the treatment of acne vulgaris

Suleyman Piskin, Erol Uzunali

Therapeutics and Clinical Risk Management 2007, 3:621-624

Published Date: 15 September 2007